推動製藥業永續性的成長機會和經營模式

Growth Opportunities and Business Models Driving Sustainability in Pharmaceuticals Industry

出版日期: 2024年01月09日 | 出版商:

Frost & Sullivan | 英文 70 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

綠色產品、設計創新和利益相關者相關人員支持永續性努力

由於《歐洲綠色新政》和《巴黎協定》，製藥（製藥）產業的法規正在發生重大變化。這些變化迫使製藥公司採取更環境永續的做法。隨著全球藥品需求的增加，製藥公司的研發和製造基礎設施不斷擴大，導致環境足跡和溫室氣體 (GHG)排放增加。因此，為了因應這些發展，地方環境法規變得更加嚴格。此外，自 COVID-19 以來，製藥公司更加意識到永續性的重要性，並正在採取措施來實現環境、社會和公司治理(ESG) 目標。公司正在適應不斷變化的法規，以保持市場競爭力。值得注意的是，投資者越來越關注 ESG 評級，並更願意根據公司的永續性努力、氣候相關資訊揭露和企業社會責任實踐來為公司提供資金。這就是我正在做的事情。

永續 & Sullivan 的這項研究重點關注製藥業的永續性，使用 6P 框架（政策、產品、流程、人員、合作夥伴關係、平台）進行了詳細討論。這項研究包括全球和區域監管機構和分析師對政策及其對製藥行業參與者和其他醫療保健相關人員的影響的主要觀點。

本研究討論了推動永續性計畫發展的主要趨勢和因素，以及採用的阻礙因素及其影響。本研究確定了支持產業相關人員加強永續性實踐的最普及和新興的經營模式經營模式，並確定了實施 6P 和實現永續發展目標的最佳實踐。它展示了製藥業公司在永續性領域的行動，並將其 ESG 計劃與 6P 框架相對應。

戰略問題

為什麼成長如此困難？
The Strategic Imperative 8（TM）
製藥業永續性的三大戰略挑戰的影響
成長機會推動Growth Pipeline Engine（TM）

成長機會分析

分析範圍
製藥業永續性和 CE 實踐的 6P 框架
依醫藥價值鏈中的措施細分
生長促進因子
成長阻礙因素
實現整個製藥價值鏈的永續性
溫室氣體排放範圍概述
促進永續性的全球政策
促進永續性的區域政策/舉措
政策影響分析
推動醫藥價值鏈永續性的趨勢
實現永續性的經營模式
四大經營模式- 影響概述
從公司到行動—永續發展目標和6P框架之間的合作

永續研究：產品

概述 -永續性產品
未來的重點領域—永續研究
特色產品 - 環保研究解決方案
永續原料 - 海洋藥物的研發

永續製造：流程

製造業的永續性- 接觸點
概述 - 實現永續性的過程
未來重點領域—永續製造
特色工藝-脫碳技術介紹
從政策到平台路徑上智慧工具的未來前景

永續包裝與分銷：合作夥伴關係

合作夥伴關係是公司之間實現永續性的機會
未來的重點領域—永續包裝與分銷
合作重點 - CE 生命週期評估 (LCA)
未來展望－技術支援的設計創新

6P的實施

J&J
AZ
輝瑞公司
PPS
安靠

成長機會宇宙

成長機會 1：永續研究，貝南設計
成長機會 2：減少醫藥價值鏈中的碳足跡
成長機會3：基於ESG的成長策略平台
成長機會4：醫藥廢棄物的永續管理
圖表列表
免責聲明

簡介目錄

Product Code: PFA4-52

Eco-friendly Products, Design Innovation, and Multi-stakeholder Partnerships Support Sustainability Initiatives

The pharmaceutical (pharma) industry is undergoing significant regulatory changes resulting from the European Green Deal and the Paris Agreement. These changes require pharma companies to adopt more environmentally sustainable practices. With the increasing demand for drugs globally, pharma R&D and manufacturing infrastructure has grown, leading to a larger environmental footprint and rising greenhouse gas (GHG) emissions. As a result, regional environmental regulations have become more stringent in response to these developments. Additionally, post-COVID-19, pharma companies have become more aware of the importance of sustainability and are adopting measures to achieve their environmental, social, and corporate governance (ESG) goals. Companies are aligning their operations with changing regulations to stay competitive in the market. Notably, investors are increasingly focused on ESG credit ratings, preferring to fund companies based on their sustainability efforts, climate-related disclosures, and corporate social responsibility practices.

This Frost & Sullivan study focuses on sustainability in the pharmaceutical industry and offers a detailed discussion on the implementation of the 6P framework, namely, policies, products, processes, people, partnerships, and platforms, by pharma value chain companies for their ESG strategy implementation and the fulfillment of United Nations Sustainable Development Goals (SDGs). The study includes key global and regional regulations and analyst perspectives on the policies and their implications for pharmaceutical industry participants and other healthcare stakeholders.

The study discusses key trends and factors driving the growth of the sustainability program as well as restraints to adoption and their implications. The study identifies the most prevalent and emerging business models that are supporting industry stakeholders in enhancing their sustainability practices and maps the best practices to 6P implementation and SDG Goal fulfillment. Pharma industry companies to action in the sustainability space are provided, and the ESG programs are mapped against the 6P framework.

Segmentation is based on the sustainability initiatives of pharma value chain companies across research (products), manufacturing (processes), and packaging and distribution (partnerships), covering detailed analysis of each segment's current focus, future implications, and prospects for stakeholders.

The ESG focus, unique sustainability initiatives, and 6P implementation case studies of Johnson & Johnson, Astra Zeneca, Pfizer, Piramal Pharma Solutions, and Amcor are discussed. The study concludes with a detailed discussion of growth opportunities in the sustainability space.

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives for Sustainability in the Pharmaceuticals Industry
Growth Opportunities Fuel the Growth Pipeline Engine™